Breaking GLP-1 updates: FDA actions, drug launches, Medicare changes, compounding enforcement.
7 articles.
Medicare GLP-1 coverage is NOW LIVE as of July 1, 2026. Here's who qualifies for the $50/month Bridge program, how to get prior auth, and whether the Bridge beats cash-pay (our 49-provider price audit).
Updated June 29, 2026: FDA issued 30 warning letters to telehealth companies June 15 for illegally marketing compounded GLP-1s. 503B permanent exclusion comment period extended to July 30, 2026 (from June 29 via FR 2026-12937). FDA proposed April 30 to permanently remove semaglutide, tirzepatide, and liraglutide from the 503B Bulks List. 503A enforcement began April 22, 2025. 503B enforcement May 22, 2025. 3-4 million patients affected. Legal alternatives: compounded tirzepatide ($149-299/mo, medical-necessity only), Wegovy $349/mo via NovoCare, or Foundayo from $149/mo self-pay.
Verified May 8, 2026, Updated July 22, 2026: On April 30, FDA proposed permanently removing semaglutide, tirzepatide, and liraglutide from the 503B outsourcing bulk list, forever, not just during shortage enforcement. Public comment period runs to July 30, 2026. Two days before that deadline, the Pharmacy Compounding Advisory Committee votes on seven peptides nominated for the 503A list (July 23-24), including MOTs-C for obesity. Both decisions land in the same week. 503A patient-specific GLP-1 compounding under medical-necessity remains unaffected.
HHS Secretary Robert F. Kennedy Jr. is considering a regulatory framework for Medicare and Medicaid GLP-1 coverage, but only for patients who have 'exhausted other options', specifically glucose monitors (~$80/month), diet changes, and exercise. Verified April 2026: what Kennedy said on CBS News April 15 and at the House Ways and Means hearing April 16, how the gate would work, and how it stacks with the already-announced Medicare GLP-1 Bridge live as of July 2026.
Verified April 11, 2026: Foundayo (orforglipron) shipped to LillyDirect patients starting April 6. First-week fill rate hit 94% within 48 hours of order. Pricing confirmed: $649/mo self-pay, $25/mo with commercial insurance + Lilly savings card. Here's exactly how to order today.
Verified April 11, 2026: The FDA issued 14 new warning letters to GLP-1 compounders between March 12 and April 8, 2026, the largest enforcement wave since the semaglutide compounding ban. Full list of affected pharmacies, what they violated, and what to do if you were a patient.
The FDA just approved Eli Lilly's Foundayo (orforglipron), the only GLP-1 weight loss pill with no food, water, or timing restrictions. Here's what it costs, how it works, and how it compares to Wegovy and Zepbound.
Ready to choose a program? Take the 60-second match quiz or see our top-ranked GLP-1 providers.
Four affiliate partners we feature, we may earn a commission.
Affiliate links, we earn a commission at no extra cost to you. These are featured partners, prioritized by our affiliate economics, not an editorial "best" ranking. The objective ranking (by methodology score) and full methodology are at glp1picks.com/best.